BridgeMD
New treatment option for Heart Failure
Official title PVP-Guided Decongestive Therapy in HF 2
ClinicalTrials.gov ID: NCT06495892
What this study is testing
What is Diuretic therapy?
Diuretic therapy is an investigational medicine, given as an once-daily infusion into a vein, being studied as a potential treatment for heart failure.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The investigators hypothesize that a simple assessment of peripheral venous pressure (PVP) will better predict the diuretic need and long-term outcomes (all cause mortality, all cause rehospitalization, emergency department visits) compared to standard evaluation.
- Phase 4: studies an already-approved treatment
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 to 99
You may be able to join if
- Hospitalization for heart failure (de novo or decompensated chronic heart failure) irrespective of left ventricular ejection fraction
- Age 18-99
- Accept to participate
You likely can't join if
- A prior history of upper extremity venous disease
- Serum creatinine ≥ 3.5 mg/dL
- Severe stenotic valvular disease
- Hypertrophic obstructive cardiomyopathy
- Withdrawal of consent
- Indwelling central venous catheter,
See the full eligibility criteria
- Hospitalization for heart failure (de novo or decompensated chronic heart failure) irrespective of left ventricular ejection fraction
- Age 18-99
- Accept to participate
- A prior history of upper extremity venous disease
- Serum creatinine ≥ 3.5 mg/dL
- Severe stenotic valvular disease
- Hypertrophic obstructive cardiomyopathy
- Withdrawal of consent
- Indwelling central venous catheter,
- Implanted left ventricular assist device
- History of heart transplantation
- Clinical diagnosis of cardiogenic shock
- Any right-to-left shunt
The study team makes the final eligibility decision.
Where it's taking place
- Ankara, Turkey (Türkiye)
- Antalya, Turkey (Türkiye)
- Edirne, Turkey (Türkiye)
- Erzurum, Turkey (Türkiye)
- Eskişehir, Turkey (Türkiye)
- Istanbul, Turkey (Türkiye)
- Izmir, Turkey (Türkiye)
- Kahramanmaraş, Turkey (Türkiye)
- Kars, Turkey (Türkiye)
- Kütahya, Turkey (Türkiye)
- Şırnak, Turkey (Türkiye)
- Tokat Province, Turkey (Türkiye)
Compensation & support
A stipend or compensation may be offered.
Compensation likely.
ClinicalTrials.gov doesn't provide a reliable structured field for payment or travel support - confirm details with the study team.
Questions & answers
Do participants get paid in this trial?
This study's listing includes signals that participants may be compensated or receive a stipend. Amounts vary and are set by the study team - confirm the details with them.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years to 99 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Ankara, Turkey (Türkiye); Antalya, Turkey (Türkiye); Edirne, Turkey (Türkiye); Erzurum, Turkey (Türkiye); Eskişehir, Turkey (Türkiye); Istanbul, Turkey (Türkiye) and 6 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.